References
- U.S. Xyrem® (Multicenter Study Group). The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003; 41: 131–135
- Mamelak M., Escriu J. M., Stokan O. The effects of gamma‐hydroxybutyrae on sleep. Biol Psych 1977; 12: 273–288
- Broughton R., Mamelak M. The treatment of narcolepsy‐cataplexy with noctural gamma‐hydroxybutyrate. Can J Neurol Sci 1979; 6: 1–6, [PUBMED], [INFOTRIEVE]
- Broughton R., Mamelak M. Effects of nocturnal gamm‐hydroxybutyrate on sleep/waking patterns in narcolepsy‐cataplexy. Can J Neurol Sci 1980; 7: 23–31, [PUBMED], [INFOTRIEVE]
- Scharf M. B., Brown D., Woods M., Brown L., Hirschowitz J. The effects and effectiveness of gamma‐hydroxybutyrate in patients with narcolepsy. J Clin Psych 1985; 46: 222–225
- Mamelak M., Scharf M. B., Woods M. Treatment of narcolepsy with gamma‐hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986; 9: 285–289, [PUBMED], [INFOTRIEVE]
- Scrima L., Hartman P. G., Johnson F. H., Jr., Hiller F. C. Efficacy of gamma‐hydroxybutyrate versus placebo in treating narcolepsy‐cataplexy: double‐blind subjective measures. Biol Psych 1989; 26: 331–343, [CROSSREF]
- Scrima L., Hartman P. G., Johnson P. G., Johnson F. H., Jr., Thomas E. E., Hiller F. C. The effects of gamma‐hydroxybutyrate on the sleep of narcolepsy patients: a double‐blind study. Sleep 1990; 13: 479–490, [PUBMED], [INFOTRIEVE]
- Lammers G. J., Arends J., Declerk A. C., Ferrari M. D., Schouwink G., Troost J. Gamma‐hydroxybutyrate and narcolepsy: a double‐blind placebo‐controlled study. Sleep 1993; 16: 216–220, [PUBMED], [INFOTRIEVE]
- U.S. Xyrem® (Multicenter Study Group). A randomized, double blind, placebo‐controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 42–49
- U.S. Xyrem® (Multicenter Study Group). A 12‐month, open‐label, multi‐center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26: 31–35
- COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms5th ed. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 1995
- Hornfeldt C. S., Pertile T. L. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not produce withdrawal symptoms. J Toxicol Clin Toxicol 2001; 59: 516
- Galloway G. P., Frederick S. L., Staggers F. E., Gonzales M., Stalcup S. A., Smith D. E. Gamma‐hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92: 96–98, [CROSSREF]
- Craig K., Gomez H. F., McManus J. L., Bania T. C. Severe gamma‐hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18: 70–76, [CROSSREF]
- Dyer J. E., Roth B., Hyma B. A. Gamma‐hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37: 147–153, [PUBMED], [INFOTRIEVE], [CROSSREF]